MedTrace Logo

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

NCT02384395 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-11-22

Study results available
· View outcomes & findings →

Summary

This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).

Conditions

  • HIV
  • Acute HIV Infection

Interventions

DRUG

Dolutegravir 50 mg

Initial therapy for AHI

DRUG

Lamivudine 300 mg

Initial therapy for AHI

DRUG

Abacavir 600 mg

Initial therapy for AHI

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Cindy Gay, MD, MPH · University of North Carolina

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2020-03-06
Completion
2021-09-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02384395 on ClinicalTrials.gov